Salient Pharmaceuticals Receives $2M Funding to Develop Treatment for Cancer Therapy Side Effect
Published On January 29, 2010 |
Salient Pharmaceuticals, Inc., a client company of the Houston Technology Center (HTC) which develops and commercializes therapeutic products for the prevention and treatment of gastro-intestinal side effects caused by disease, chemotherapy or radiation, received a $2m commercialization award from the Texas Emerging Technology Fund (TETF).
The new funds will be used fot the commercialization of Salient’s CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.
Established in 2005, the TETF supports start-up companies in growing faster. Including Salient, the company has announced awards to 31 Gulf Coast region companies, eligible for almost $30m in assistance.
The HTC, a business accelerator and the largest technology business incubator in Texas, serves as the Gulf Coast Regional Center for Innovation and Commercialization (GCRCIC) for the TETF, collaborating with the Greater Houston Partnership, area universities, community volunteers and economic development organizations within its 30-county region.
The GCRCIC is responsible for processing all funding applications and supporting emerging technology companies in its region.